Haemostasis Flashcards

1
Q

What is haemostasis?

A

the cellular and biochemical processes that enable both the specific and regulated cessation of bleeding in response to vascular insult

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the purpose of haemostasis?

A
  • prevention of blood loss from intact vessels
  • arrest bleeding from injured vessels
  • enable tissue repair
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the overall mechanism of haemostasis?

A
  • vessel constriction–> vascular smooth muscle cells contract locally to limit blood flow to injured vessel
  • 1y- formation of unstable platelet plug w/ platelet adhesion+aggregation to limit blood loss+provide surface for coagulation
  • 2y- stabilisation of plug w/ fibrin–> blood coagulation to stop blood loss
  • fibrinolysis- vessel repair+dissolution of clot to restore vessel integrity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is thrombocytopenia and what are its causes?

A

low numbers of platelets

  • reduction in production by bone marrow e.g. leukaemia, vitamin B12 deficiency
  • accelerated clearance of platelets e.g. immune thrombocytopenia (ITP) (common cause), or disseminated intravascular coagulation (DIC)
  • pooling and destruction in enlarged spleen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the causes of impaired function of platelets?

A
  • -> hereditary absence of glycoproteins or storage granules (rare)
    e. g. - Glanzmann’s thrombasthenia- absence of GPIIbIIIa receptor on platelets
  • Bernard Soulier syndrome- absence of GPIb receptors
  • Storage pool disease: reduction in granular contents of platelets

–> acquired due to drugs e.g. aspirin (irreversibly blocks COX), NSAIDs, clopidogrel (irreversibly blocks ADP receptor on platelets) (common)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is Von Willebrand disease?

A
  • hereditary (common): autosomal inheritance- deficiency (type 1 or 3) or abnormal function (type 2)
  • acquired due to antibody (rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the causes of vessel wall disorders?

A
  • inherited (rare) e.g. Ehlers-Danlos syndrome (abnormalities in collagen)
  • acquired (common) e.g. steroids, age (senile purpura), vasculitis, scurvy (vitamin C deficiency)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the clinical features of primary haemostatic disorders?

A
  • immediate
  • prolonged bleeding from cuts
  • prolonged nose bleeds/epistaxis (>20min)
  • prolonged gum bleeding
  • heavy menstrual bleeding (menorrhagia)
  • sponaneous/easy bruising (ecchymosis)
  • prolonged bleeding after trauma or surgery

N.B. petechiae common of thrombocytopenia

N.B. purpura- platelet or vascular disorders- do not blanch when pressure is applied (and bigger than petechiae)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do you test for primary haemostatic disorders?

A
  • platelet count, platelet morphology
  • bleeding time (PFA100 in lab)
  • assays of von Willebrand Factor
  • clinical observation
    N.B. coagulation screen (PT, APTT) usually normal except in severe VWD cases where FVIII is low
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How do we treat primary haemostatic disorders?

A
  • replace missing factor/platelets e.g. VWF containing concentrates, or platelets–> either prophylactic (before surgery) or therapeutic (following bleeding)
  • stop drugs e.g. aspirin/NSAIDs
  • immunosuppression e.g. prednisolone
  • splenectomy for ITP
  • desmopressin (DDAVP) for releasing endogenous stores of VWF in mild disorders
  • tranexamic acid (antifibrinolytic)
  • fibrin glue/spray during surgery
  • other approaches e.g. COCP for menorrhagia

treat underlying cause + replace as necessary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the role of coagulation?

A

to generate thrombin (factor IIa), which will convert fibrinogen to fibrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the 3 broad causes of coagulation factor disorders?

A
  1. deficiency of coagulation factor production:
    - hereditary: factor VIII/IV (haemophilia A/B)
    - acquired: liver disease, anticoagulant drugs (warfarin, DOACs)
  2. dilution: acquired- blood transfusion (inadequate replacement of plasma)
  3. increased consumption: acquired- DIC (common), autoantibodies (rare)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the hallmark of haemophilia?

A
  • haemarthrosis: spontaneous joint bleeding
  • chronic haemarthrosis–> joint deformity and muscle wasting
  • seen in patients who come from other parts of the world who haven’t had access to care
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why does liver failure result in decreased production of coagulation factors?

A

because most coagulation factors are synthesised in liver (except VWF and factor V)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why does major haemorrhage require transfusion of plasma as well as red cells and platelets?

A

to avoid a dilution effect with reduction in coagulation factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is disseminated intravascular coagulation?

A
  • generalised, unregulated activation of coagulation (tissue factor)
  • triggered by sepsis, cancer, major tissue damage, inflammation, severe pre-eclampsia
  • widespread consumption and depletion of coagulation factors
  • platelets consumed–> thrombocytopenia
  • activation of fibrinolysis depletes fibrinogen–> raised D-dimer (breakdown product of fibrin)
  • deposition of fibrin in vessels causes organ failure and receiving cell fragmentation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the clinical features/ bleeding pattern of coagulation disorders?

A
  • superficial cuts do not bleeds (as platelet plug is sufficient)
  • bruising is common, but nosebleeds are rare
  • spontaneous bleeding is deep, into muscles and joints
  • bleeding after trauma may be delayed and prolonged
  • bleeding frequently restarts after stopping
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How do you test for coagulation disorders?

A
  • screening tests (‘clotting screen’): PT, APTT, full blood count (platelets)
  • coagulation factor assays (e.g. factor VIII)
  • test for inhibitors
19
Q

What could cause a prolongation of both PT and APTT?

A
  • liver disease
  • anticoagulant drugs e.g. warfarin
  • DIC (platelets and D-dimer)
  • dilution following red cell transfusion
20
Q

What could cause a prolongation of PT?

A

factor VII deficiency

21
Q

What could cause a prolongation of APTT?

A
  • haemophilia A
  • haemophilia B
  • factor XI deficiency
  • factor XII deficiency
22
Q

What are the different kinds of factor replacement therapy?

A
  • plasma (FFP): contains all coagulation factors
  • cryoprecipitate: rich in fibrinogen, factor VIII, VWF and factor XIII
  • single factor concentrates: available for all except factor V
  • prothrombin complex concentrates (PCCs): factors II, VII, IX and X
  • recombinant forms of factor VIII and IX: on demand to treat bleeds, or prophylactic
23
Q

How does pulmonary embolism (PE) present?

A
  • tachycardia
  • hypoxia
  • shortness of breath
  • chest pain
  • haemoptysis in more serious cases
  • sudden death
24
Q

How does deep vein thrombosis (DVT) present?

A
  • painful leg
  • swelling
  • warm
  • red
  • may embolise to lungs
  • post thrombotic syndrome–> long standing pain and swelling due to damage to valves
25
Q

What is thrombosis?

A

inappropriate, intravascular coagulation- venous or arterial –> obstructs flow and may embolise to lungs

26
Q

What is Virchow’s triad?

A

3 contributory factors to thrombosis:

  • blood changes: dominant in venous thrombosis
  • vessel wall changes: dominant in arterial thrombosis
  • blood flow changes: contributes to both arterial and venous thrombosis
27
Q

What is thrombophilia?

A

increased risk of venous thrombosis:

  • thrombosis may present at young age
  • ‘spontaneous thrombosis’- unprovoked
  • multiple thromboses
  • thrombosis even whilst anticoagulated
28
Q

What are examples of inherited thrombophilias?

A
  • anticoagulant deficiency: antithrombin, protein C or protein S
  • procoagulant excess: factor V leiden, factor VIII, prothrombin (factor II)
29
Q

What role does the vessel wall play in venous thrombosis?

A

many proteins active in coagulation are expressed on the surface of endothelial cells- and their expression is altered in inflammation

30
Q

How do changes in blood flow contribute to thrombosis?

A

stasis/reduced flow increases risk of thrombosis

e.g. surgery, long haul flight, pregnancy (due to compression)

31
Q

How do we treat venous thrombosis?

A

assess risk

  • prevention: thromboprophylaxis
  • reduce risk of recurrence/extension: lower procoagulant factors e.g. warfarin, DOACs or increase anticoagulant activity e.g. heparin
32
Q

What are indications for anticoagulation?

A
  • preventative (thromboprophylaxis): e.g. following surgery, during hospital admission, during pregnancy
  • venous thrombosis: initial treatment to minimise clot extension/embolisation (<3months), long term treatment to reduce risk of recurrence
  • atrial fibrillation: ~1% of pop., to reduce risk of embolic stroke
  • mechanical prosthetic heart valves (risk of stroke high)
33
Q

What is the difference in administration between unfractionated heparin (UFH) and low molecular weight heparin (LMWH)?

A

UFH- intravenous administration

LMWH- subcutaneous injection

34
Q

How does unfractionated heparin act?

A

enhances antithrombin by binding to it and changing its shape, giving it a greater affinity for factor Xa AND thrombin
INTRAVENOUS

35
Q

How does low molecular weight heparin act?

A

enhances antithrombin activity (but much less than UFH)–> heparin pentasaccharide sequences bind to antithrombin, enhancing affinity to factor Xa
SUBCUTANEOUS

36
Q

What effects do UFH and LMWH have on coagulation tests?

A
  • prolongation of APTT
  • use APTT to monitor effect of UFH, as it varies between individuals receiving IV infusions
  • LMWH doesn’t require monitoring, as more predictable effect (use anti-Xa activity to monitor if needed)
37
Q

How does warfarin act and how do we reverse it?

A
  • blocks recycling of vitamin K
  • vit K cannot be reduced back down to the hydroquinone state and reused for gamma carboxylation–> reduces production of functional coagulation factors (slowly)
  • reversible by vit K administration (slowly) or infusion of coagulation factors (rapid)
38
Q

Why does warfarin require monitoring?

A
  • complicated metabolism–> many dietary, physiological and drug interactions
  • narrow therapeutic index, and effect variable between individuals
39
Q

What are the side effects of warfarin?

A
  • bleeding
  • skin necrosis (due to severe protein C deficiency–> coagulation factor imbalance leads to paradoxical activation of coagulation, causing thrombosis predominantly in adipose tissues)
  • purple toe syndrome due to bleeding from disrupted atheromatous plaques
  • embryopathy- chondrodysplasia punctata due to early fusion of epiphyses
40
Q

How do you monitor individuals being treated with warfarin?

A

INR (International Normalised Ratio)
- standardised measure correcting for different thromboplastins used in lab to measure PT
- target INR usually = 2-3
- without anticoagulants normal INR = 1
(risk of bleeding increases with increased INR)

41
Q

Why might someone be resistant to warfarin?

A
  • diet- eating high vitamin K
  • lack of compliance
  • drug interactions: reduced binding or increased metabolism
42
Q

What are DOACs (Direct Oral Anticoagulants)?

A
  • direct factor Xa inhibitors: rivaroxaban, apixaban, edoxaban
  • direct factor IIa/thrombin inhibitor: dabigatran
43
Q

What are the differences between warfarin and DOACs?

A
  • warfarin: slow onset, DOACs: rapid
  • warfarin: variable dosing, DOACs: fixed
  • warfarin: food effects and drug interactions, DOACs: far fewer interactions
  • warfarin: requires monitoring, DOACs: does not
  • warfarin: no kidney involvement, DOACs: some renal dependence
  • warfarin: vit K and PCCs for reversibility, DOACs: specific antidotes are very expensive and not yet fully available for some
  • risk of bleeding for DOACs lower than for warfarin